Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema

American Journal of Respiratory Cell and Molecular Biology

Volumn 50, Issue 1, 2014, Pages 18-29

  Ikeda, Genyo ^a   Miyahara, Nobuaki ^a   Koga, Hikari ^a   Fuchimoto, Yasuko ^a   Waseda, Koichi ^a   Kurimoto, Etsuko ^a   Taniguchi, Akihiko ^a   Tanimoto, Yasushi ^a   Kataoka, Mikio ^a   Tanimoto, Mitsune ^a   Kanehiro, Arihiko ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Cysteinyl leukotriene; Cysteinyl leukotriene receptor; Overlap of asthma and chronic obstructive pulmonary disease

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE B4; MACROPHAGE INFLAMMATORY PROTEIN 2; MONTELUKAST; OVALBUMIN; PANCREATIC ELASTASE; PEPTIDOLEUKOTRIENE; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; EXPERIMENTAL EMPHYSEMA; FEMALE; INFLAMMATORY CELL; LUNG COMPLIANCE; LUNG DEVELOPMENT; LUNG EMPHYSEMA; LUNG LAVAGE; LYMPHOCYTE COUNT; MORPHOMETRICS; MOUSE; NEUTROPHIL; NONHUMAN; PROVOCATION TEST; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION;

ACETATES; ANIMALS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; CYSTEINE; FEMALE; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LUNG; MICE; MICE, INBRED BALB C; PNEUMONIA; PULMONARY EMPHYSEMA; QUINOLINES; RECEPTORS, LEUKOTRIENE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891783155     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0418OC     Document Type: Article

References (49)

1. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J 2002; 20: 799-805. (Pubitemid 35175112)
2. Welte T, Groneberg DA. Asthma and COPD. Exp Toxicol Pathol 2006; 57: 35-40. (Pubitemid 43766071)
3. Kim SR, Rhee YK. Overlap between asthma and COPD: where the two diseases converge. Allergy Asthma Immunol Res 2010; 2: 209-214.
4. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 176-183.
5. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008; 121: 1365-1371.
6. Fauler J, Frölich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27: 43-47. (Pubitemid 27065172)
7. Thien FC, Walters EH. Eicosanoids and asthma: an update. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 271-288.
8. McMillan RM. Leukotrienes in respiratory disease. Paediatr Respir Rev 2001; 2: 238-244. (Pubitemid 34460744)
9. Mitsunobu F, Mifune T, Hosaki Y, Ashida K, Tsugeno H, Okamoto M, Takata S, Tanizaki Y. Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2001; 107: 492-498. (Pubitemid 32210030)
10. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009; 124: 406-414, quiz 415-416.
11. Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 2012; 142: 347-357.
12. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergeninduced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718-728.
13. Ramires R, Caiaffa MF, Tursi A, Haeggström JZ, Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004; 324: 815-821. (Pubitemid 39345588)
14. Anderson R, Theron AJ, Gravett CM, Steel HC, Tintinger GR, Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2009; 156: 105-115.
15. Woszczek G, Chen L-Y, Alsaaty S, Nagineni S, Shelhamer JH. Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. J Immunol 2010; 184: 2219-2225.
16. Fuchimoto Y, Kanehiro A, Miyahara N, Koga H, Ikeda G, Waseda K, Tanimoto Y, Ueha S, Kataoka M, Gelfand EW, et al. Requirement for chemokine receptor 5 in the development of allergen-induced airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2011; 45: 1248-1255.
17. Lee YM, Miyahara N, Takeda K, Prpich J, Oh A, Balhorn A, Joetham A, Gelfand EW, Dakhama A. IFN-g production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 2007; 177: 208-218.
18. Waseda K, Miyahara N, Kanehiro A, Ikeda G, Koga H, Fuchimoto Y, Kurimoto E, Tanimoto Y, Kataoka M, Tanimoto M, et al. Blocking the leukotriene B4 receptor 1 inhibits late-phase airway responses in established disease. Am J Respir Cell Mol Biol 2011; 45: 851-857.
19. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ. Overexpression of tumor necrosis factor-αlpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 280: L39-L49.
20. Dunnill MS. Evaluation of a simple method of sampling the lung for quantitative histological analysis. Thorax 1964; 19: 443-448.
21. Hamakawa H, Bartolák-Suki E, Parameswaran H, Majumdar A, Lutchen KR, Suki B. Structure-function relations in an elastase-induced mouse model of emphysema. Am J Respir Cell Mol Biol 2011; 45: 517-524.
22. Parameswaran H, Majumdar A, Ito S, Alencar AM, Suki B. Quantitative characterization of airspace enlargement in emphysema. J Appl Physiol 2006; 100: 186-193. (Pubitemid 43671107)
23. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
24. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005; 99: 444-450. (Pubitemid 40347827)
25. Gueli N, Verrusio W, Linguanti A, De Santis W, Canitano N, Ippoliti F, Marigliano V, Cacciafesta M. Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report. Arch Gerontol Geriatr 2011; 52: e36-e39.
26. Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease $ 3: Experimental animal models of pulmonary emphysema. Thorax 2002; 57: 908-914. (Pubitemid 35178618)
27. Snider GL. Experimental studies on emphysema and chronic bronchial injury. Eur J Respir Dis Suppl 1986; 146: 17-35. (Pubitemid 17180179)
28. Shigemura N, Sawa Y, Mizuno S, Ono M, Ohta M, Nakamura T, Kaneda Y, Matsuda H. Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation 2005; 111: 1407-1414. (Pubitemid 40396807)
29. Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JAD Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, et al.; Copd Clinical Research Network. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 2011; 8: 21-29.
30. Miyahara N, Takeda K, Miyahara S, Matsubara S, Koya T, Joetham A, Krishnan E, Dakhama A, Haribabu B, Gelfand EW. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005; 172: 161-167. (Pubitemid 40981188)
31. Miyahara N, Miyahara S, Takeda K, Gelfand EW. Role of the LTB4/ BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergol Int 2006; 55: 91-97. (Pubitemid 43973880)
32. Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J, Shultz LD, Tager AM, Luster AD, Dakhama A, et al. The leukotriene B4 receptor (BLT1) is required for effector CD81 T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006; 176: 3157-3164.
33. Miyahara N, Takeda K, Miyahara S, Taube C, Joetham A, Koya T, Matsubara S, Dakhama A, Tager AM, Luster AD, et al. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD81 T cells and airway hyperresponsiveness. J Immunol 2005; 174: 4979-4984.
34. Miyahara N, Ohnishi H, Miyahara S, Takeda K, Matsubara S, Matsuda H, Okamoto M, Loader JE, Joetham A, Tanimoto M, et al. Leukotriene B4 release from mast cells in IgE-mediated airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2009; 40: 672-682.
35. Corhay JL, Henket M, Nguyen D, Duysinx B, Sele J, Louis R. Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest 2009; 136: 1047-1054.
36. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007; 119: 1055-1062, quiz 1063-1064. (Pubitemid 46654167)
37. Ohnishi H, Miyahara N, Gelfand EW. The role of leukotriene B(4) in allergic diseases. Allergol Int 2008; 57: 291-298.
38. Diamant Z, Hiltermann JT, van Rensen EL, Callenbach PM, Veselic- Charvat M, van der Veen H, Sont JK, Sterk PJ. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997; 155: 1247-1253. (Pubitemid 27172766)
39. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157: 1381-1389.
40. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835-841. (Pubitemid 28459539)
41. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117(2, Suppl)10S-14S. (Pubitemid 30111557)
42. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453. (Pubitemid 27085784)
43. Kumlin M, Dahlén SE. Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim Biophys Acta 1990; 1044: 201-210. (Pubitemid 20151275)
44. Schleimer RP, MacGlashan DW Jr, Peters SP, Pinckard RN, Adkinson NF Jr, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986; 133: 614-617. (Pubitemid 16127246)
45. Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151: 1785-1790. (Pubitemid 27527941)
46. Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639. (Pubitemid 27505536)
47. Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN. Increased airway granzyme B and perforin in current and ex-smoking COPD subjects. COPD 2006; 3: 179-187. (Pubitemid 44949057)
48. Shiratsuchi N, Asai K, Kanazawa H, Kyoh S, Tochino Y, Kodama T, Hirata K. Measurement of soluble perforin, a marker of CD81 T lymphocyte activation in epithelial lining fluid. Respir Med 2011; 105: 1885-1890.
49. Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, Siafakas NM. Perforin expression and cytotoxic activity of sputum CD81 lymphocytes in patients with COPD. Chest 2004; 125: 71-76. (Pubitemid 38114566)